Brooklyn Investment Group Has $181,000 Position in Takeda Pharmaceutical Co. $TAK

Brooklyn Investment Group boosted its position in Takeda Pharmaceutical Co. (NYSE:TAK) by 890.7% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 12,176 shares of the company’s stock after purchasing an additional 10,947 shares during the period. Brooklyn Investment Group’s holdings in Takeda Pharmaceutical were worth $181,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. GAMMA Investing LLC increased its holdings in Takeda Pharmaceutical by 22.6% in the 1st quarter. GAMMA Investing LLC now owns 7,042 shares of the company’s stock worth $105,000 after purchasing an additional 1,296 shares in the last quarter. Allspring Global Investments Holdings LLC increased its holdings in Takeda Pharmaceutical by 5.4% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 21,373 shares of the company’s stock worth $319,000 after purchasing an additional 1,098 shares in the last quarter. Russell Investments Group Ltd. increased its holdings in Takeda Pharmaceutical by 48.6% in the 4th quarter. Russell Investments Group Ltd. now owns 45,324 shares of the company’s stock worth $600,000 after purchasing an additional 14,831 shares in the last quarter. Farther Finance Advisors LLC increased its holdings in Takeda Pharmaceutical by 29.2% in the 1st quarter. Farther Finance Advisors LLC now owns 4,620 shares of the company’s stock worth $69,000 after purchasing an additional 1,045 shares in the last quarter. Finally, Vontobel Holding Ltd. acquired a new position in Takeda Pharmaceutical in the 1st quarter worth about $262,000. Institutional investors and hedge funds own 9.17% of the company’s stock.

Takeda Pharmaceutical Price Performance

Shares of TAK opened at $15.4750 on Thursday. Takeda Pharmaceutical Co. has a 12-month low of $12.80 and a 12-month high of $15.56. The business has a 50-day simple moving average of $14.80 and a two-hundred day simple moving average of $14.65. The company has a quick ratio of 0.59, a current ratio of 1.16 and a debt-to-equity ratio of 0.60. The stock has a market cap of $49.24 billion, a PE ratio of 51.58 and a beta of 0.22.

Takeda Pharmaceutical (NYSE:TAK) last issued its earnings results on Wednesday, July 30th. The company reported $0.52 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.47 by $0.05. The business had revenue of $7.45 billion during the quarter, compared to analysts’ expectations of $7.96 billion. Takeda Pharmaceutical had a return on equity of 10.50% and a net margin of 3.20%. Takeda Pharmaceutical has set its FY 2025 guidance at 3.360-3.360 EPS. Analysts anticipate that Takeda Pharmaceutical Co. will post 1.64 earnings per share for the current fiscal year.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.